Its main statistical benefit is improved comparability where outcomes differ across subgroups. By allocating participants separately within categories such as age, disease severity, or study site, the treatment groups retain a more similar distribution of influential characteristics. This can reduce the influence of confounding variables and increase the precision of comparisons, making estimated treatment effects easier to interpret.
Strata should reflect characteristics that may matter for outcomes or for interpreting treatment effects, including age, disease severity, and study site. The overview supports using predefined subgroups rather than creating categories after treatment assignment. This planning step focuses the randomization on known population differences, helping preserve balance where variation among subgroups could otherwise affect group comparisons.
Random allocation remains essential because subgroup membership alone does not determine treatment assignment. After participants are placed into a stratum, chance determines whether they enter one treatment group or another, using equal or specified proportions. Thus, stratification addresses balance across important categories, while randomization limits systematic assignment differences within those categories.
Investigators first divide the study population into predefined strata based on selected characteristics. They then assign participants separately within each subgroup, using random allocation to place them into treatment groups. Assignments may follow equal numbers or another specified proportion. This process produces groups that preserve the intended balance across the characteristics chosen for stratification.
Stratified randomization is especially useful in clinical trials, epidemiological studies, and experimental research when important participant or study characteristics may influence outcomes. It is valuable when outcomes differ among subgroups, because balancing those subgroups across treatment groups can make comparisons more precise and strengthen the validity and interpretability of estimated treatment effects.
Analyses based on this design can support comparisons of treatment groups while accounting for the distribution of selected characteristics across them. The key outcome is not merely similar group size, but greater confidence that differences in observed outcomes are less likely to reflect imbalance in age, disease severity, or study site. This supports clearer interpretation of estimated treatment effects.